Bio-Techne Corporation announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.46 USD | +16.22% | +15.65% | -4.80% |
May. 01 | Equity Markets Mostly Fall After Fed Leaves Rate Unchanged | MT |
May. 01 | Equity Markets Mostly Fall After Fed Leaves Rate Unchanged | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.80% | 11.55B | |
+0.67% | 42.4B | |
+44.30% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.38% | 9.5B |
- Stock Market
- Equities
- TECH Stock
- News Bio-Techne Corporation
- Bio-Techne Corporation Appoints Kim Kelderman as Chief Executive Officer Effective February 1, 2024